National Center for AIDS/STD Control and Prevention, China CDC
Quick facts
Marketed products
- Regimen：BIC+FTC+TAF · Infectious Disease / Virology
This combination regimen inhibits HIV reverse transcriptase and integrase to suppress viral replication and prevent AIDS progression. - Regimen:TDF+3TC+EFV · Infectious Disease / Virology
This combination regimen inhibits HIV reverse transcriptase and integrase through three antiretroviral agents, preventing viral replication and reducing viral load.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- National Center for AIDS/STD Control and Prevention, China CDC portfolio CI brief
- National Center for AIDS/STD Control and Prevention, China CDC pipeline updates RSS
Frequently asked questions about National Center for AIDS/STD Control and Prevention, China CDC
What are National Center for AIDS/STD Control and Prevention, China CDC's marketed drugs?
Top marketed products include Regimen：BIC+FTC+TAF, Regimen:TDF+3TC+EFV.
Related
- Regimen：BIC+FTC+TAF · Infectious Disease / Virology
- Regimen:TDF+3TC+EFV · Infectious Disease / Virology
- Sector hub: All tracked pharma companies